Nimotuzumab in Children With Intrinsic Pontine Glioma
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
Determination of efficiency of nimotuzumab in children with diffuse intrinsic pontine glioma.
Details
Lead Sponsor:
Oncoscience AG
Collaborators:
Burdenko Neurosurgery Institute Children`s Medical Hospital, University of Bonn, Germany Children`s Medical Hospital, University of Homburg/Saar, Homburg/Saar, Germany Children`s Medical Hospital, University of Leipzig, Leipzig, Germany Children`s Medical Hospital, University of Muenster, Muenster, Germany Children's Medical Hospital, Medical School Hannover, Hannover, Germany Children's Medical Hospital, University of Bonn, Germany Children's Medical Hospital, University of Homburg/Saar, Homburg/Saar, Germany Children's Medical Hospital, University of Leipzig, Leipzig, Germany Children's Medical Hospital, University of Muenster, Muenster, Germany CRM Biometrics GmbH Dept. of Statistics, University of Dortmund, Germany Dr. von Haunersches Children's Medical Hospital, University of Munich, Germany Hannover Medical School Heinrich-Heine University, Duesseldorf Istituto Nazinonale Tumori, Div. of Paediatric Oncology,Milano, Italy University of Wuerzburg